What is the financial structure and strategic rationale of GSK's acquisition of Nuvalent?

GSK agreed to acquire Nuvalent for $10.6 billion in an all-cash deal, valuing Nuvalent at approximately $124 per share—a 40% premium to its last closing price. Net of cash acquired, GSK's aggregate investment is estimated at $9.4 billion. Strategically, the acquisition aims to boost GSK's lung cancer portfolio, provide 'significant new treatment options' for lung cancer patients, and create a platform to expand with Ris-Rez, GSK's experimental antibody-drug conjugate currently in late-stage testing. The deal is expected to add to GSK's sales and operating profit in 2027 and to core earnings per share in 2029.

How does this acquisition align with GSK CEO Luke Miels' broader corporate goals?

The acquisition directly supports GSK CEO Luke Miels' mandate to convince investors that the company can achieve a revenue target of more than £40 billion by 2031, strengthen its drug pipeline, and manage the impending 2028 patent expiry of its HIV medicine dolutegravir. By adding Nuvalent’s lung cancer assets, GSK bolsters its oncology pipeline—addressing both pipeline depth and therapeutic diversification—while positioning itself for near- to mid-term commercial growth, as evidenced by the anticipated contributions to sales, operating profit (from 2027), and core earnings per share (from 2029).